カテゴリー： QYResearch, 世界, 医療/バイオ

循環器疾患看護薬のグローバル市場2023年：降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬

◆英語タイトル：Global Cardiovascular Disease Nursing Drugs Market Research Report 2023

QYResearchが発行した調査報告書（QYR23MA8714）◆商品コード：QYR23MA8714
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2023年3月
◆ページ数：95
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の循環器疾患看護薬市場について調査・分析し、世界の循環器疾患看護薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬）、用途別セグメント分析（病院、医学研究所、診療所、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Crestor、Zetia、Vytorin、Letairis、Tracleer、Bystolic、Opsumit、Ranexa、Azilva、Remodulinなどが含まれています。世界の循環器疾患看護薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、循環器疾患看護薬市場規模を推定する際に考慮しました。

・循環器疾患看護薬市場の概要
- 製品の定義
- 循環器疾患看護薬のタイプ別セグメント
- 世界の循環器疾患看護薬市場規模：タイプ別分析（降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬）
- 循環器疾患看護薬の用途別セグメント
- 世界の循環器疾患看護薬市場規模：用途別分析（病院、医学研究所、診療所、その他）
- 世界の循環器疾患看護薬市場規模予測（2018年-2029年）
- 循環器疾患看護薬の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 循環器疾患看護薬市場の競争状況およびトレンド

・循環器疾患看護薬の地域別市場規模
- 北米の循環器疾患看護薬市場規模（2018年-2029年）
- アメリカの循環器疾患看護薬市場規模（2018年-2029年）
- ヨーロッパの循環器疾患看護薬市場規模（2018年-2029年）
- アジア太平洋の循環器疾患看護薬市場規模（2018年-2029年）
- 中国の循環器疾患看護薬市場規模（2018年-2029年）
- 日本の循環器疾患看護薬市場規模（2018年-2029年）
- 韓国の循環器疾患看護薬市場規模（2018年-2029年）
- インドの循環器疾患看護薬市場規模（2018年-2029年）
- オーストラリアの循環器疾患看護薬市場規模（2018年-2029年）
- 中南米の循環器疾患看護薬市場規模（2018年-2029年）
- 中東・アフリカの循環器疾患看護薬市場規模（2018年-2029年）

・タイプ別セグメント：降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬
- 世界の循環器疾患看護薬のタイプ別販売量（2018年-2023年）
- 世界の循環器疾患看護薬のタイプ別売上（2018年-2023年）
- 世界の循環器疾患看護薬のタイプ別価格

・用途別セグメント：病院、医学研究所、診療所、その他
- 世界の循環器疾患看護薬の用途別販売量（2018年-2023年）
- 世界の循環器疾患看護薬の用途別売上（2018年-2023年）
- 世界の循環器疾患看護薬の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Crestor、Zetia、Vytorin、Letairis、Tracleer、Bystolic、Opsumit、Ranexa、Azilva、Remodulin

・産業チェーンと販売チャネルの分析
- 循環器疾患看護薬産業チェーン分析
- 循環器疾患看護薬の主要原材料
- 循環器疾患看護薬の販売チャネル
- 循環器疾患看護薬のディストリビューター
- 循環器疾患看護薬の主要顧客

・循環器疾患看護薬市場ダイナミクス
- 循環器疾患看護薬の業界動向
- 循環器疾患看護薬市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

Highlights
The global Cardiovascular Disease Nursing Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Cardiovascular Disease Nursing Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cardiovascular Disease Nursing Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Cardiovascular Disease Nursing Drugs include Crestor, Zetia, Vytorin, Letairis, Tracleer, Bystolic, Opsumit, Ranexa and Azilva, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cardiovascular Disease Nursing Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiovascular Disease Nursing Drugs.
The Cardiovascular Disease Nursing Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cardiovascular Disease Nursing Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cardiovascular Disease Nursing Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Crestor
Zetia
Vytorin
Letairis
Tracleer
Bystolic
Opsumit
Ranexa
Azilva
Remodulin
Segment by Type
Antihypertensive Drugs
Antianginal Drugs
Anticoagulants
Antilipidemic Drugs
Anti-heart Failure Drugs
Antiarrhythmic Drugs
Segment by Application
Hospital
Institute of Medicine
Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Cardiovascular Disease Nursing Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Cardiovascular Disease Nursing Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Cardiovascular Disease Nursing Drugs Market Overview
1.1 Product Overview and Scope of Cardiovascular Disease Nursing Drugs
1.2 Cardiovascular Disease Nursing Drugs Segment by Type
1.2.1 Global Cardiovascular Disease Nursing Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Antihypertensive Drugs
1.2.3 Antianginal Drugs
1.2.4 Anticoagulants
1.2.5 Antilipidemic Drugs
1.2.6 Anti-heart Failure Drugs
1.2.7 Antiarrhythmic Drugs
1.3 Cardiovascular Disease Nursing Drugs Segment by Application
1.3.1 Global Cardiovascular Disease Nursing Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Institute of Medicine
1.3.4 Clinic
1.3.5 Others
1.4 Global Cardiovascular Disease Nursing Drugs Market Size Estimates and Forecasts
1.4.1 Global Cardiovascular Disease Nursing Drugs Revenue 2018-2029
1.4.2 Global Cardiovascular Disease Nursing Drugs Sales 2018-2029
1.4.3 Global Cardiovascular Disease Nursing Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Cardiovascular Disease Nursing Drugs Market Competition by Manufacturers
2.1 Global Cardiovascular Disease Nursing Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Cardiovascular Disease Nursing Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Cardiovascular Disease Nursing Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Cardiovascular Disease Nursing Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cardiovascular Disease Nursing Drugs, Product Type & Application
2.7 Cardiovascular Disease Nursing Drugs Market Competitive Situation and Trends
2.7.1 Cardiovascular Disease Nursing Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cardiovascular Disease Nursing Drugs Players Market Share by Revenue
2.7.3 Global Cardiovascular Disease Nursing Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cardiovascular Disease Nursing Drugs Retrospective Market Scenario by Region
3.1 Global Cardiovascular Disease Nursing Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Cardiovascular Disease Nursing Drugs Global Cardiovascular Disease Nursing Drugs Sales by Region: 2018-2029
3.2.1 Global Cardiovascular Disease Nursing Drugs Sales by Region: 2018-2023
3.2.2 Global Cardiovascular Disease Nursing Drugs Sales by Region: 2024-2029
3.3 Global Cardiovascular Disease Nursing Drugs Global Cardiovascular Disease Nursing Drugs Revenue by Region: 2018-2029
3.3.1 Global Cardiovascular Disease Nursing Drugs Revenue by Region: 2018-2023
3.3.2 Global Cardiovascular Disease Nursing Drugs Revenue by Region: 2024-2029
3.4 North America Cardiovascular Disease Nursing Drugs Market Facts & Figures by Country
3.4.1 North America Cardiovascular Disease Nursing Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Cardiovascular Disease Nursing Drugs Sales by Country (2018-2029)
3.4.3 North America Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cardiovascular Disease Nursing Drugs Market Facts & Figures by Country
3.5.1 Europe Cardiovascular Disease Nursing Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Cardiovascular Disease Nursing Drugs Sales by Country (2018-2029)
3.5.3 Europe Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cardiovascular Disease Nursing Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Cardiovascular Disease Nursing Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Cardiovascular Disease Nursing Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Cardiovascular Disease Nursing Drugs Market Facts & Figures by Country
3.7.1 Latin America Cardiovascular Disease Nursing Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Cardiovascular Disease Nursing Drugs Sales by Country (2018-2029)
3.7.3 Latin America Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cardiovascular Disease Nursing Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Cardiovascular Disease Nursing Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Cardiovascular Disease Nursing Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Cardiovascular Disease Nursing Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cardiovascular Disease Nursing Drugs Sales by Type (2018-2029)
4.1.1 Global Cardiovascular Disease Nursing Drugs Sales by Type (2018-2023)
4.1.2 Global Cardiovascular Disease Nursing Drugs Sales by Type (2024-2029)
4.1.3 Global Cardiovascular Disease Nursing Drugs Sales Market Share by Type (2018-2029)
4.2 Global Cardiovascular Disease Nursing Drugs Revenue by Type (2018-2029)
4.2.1 Global Cardiovascular Disease Nursing Drugs Revenue by Type (2018-2023)
4.2.2 Global Cardiovascular Disease Nursing Drugs Revenue by Type (2024-2029)
4.2.3 Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Cardiovascular Disease Nursing Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Cardiovascular Disease Nursing Drugs Sales by Application (2018-2029)
5.1.1 Global Cardiovascular Disease Nursing Drugs Sales by Application (2018-2023)
5.1.2 Global Cardiovascular Disease Nursing Drugs Sales by Application (2024-2029)
5.1.3 Global Cardiovascular Disease Nursing Drugs Sales Market Share by Application (2018-2029)
5.2 Global Cardiovascular Disease Nursing Drugs Revenue by Application (2018-2029)
5.2.1 Global Cardiovascular Disease Nursing Drugs Revenue by Application (2018-2023)
5.2.2 Global Cardiovascular Disease Nursing Drugs Revenue by Application (2024-2029)
5.2.3 Global Cardiovascular Disease Nursing Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Cardiovascular Disease Nursing Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Crestor
6.1.1 Crestor Corporation Information
6.1.2 Crestor Description and Business Overview
6.1.3 Crestor Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Crestor Cardiovascular Disease Nursing Drugs Product Portfolio
6.1.5 Crestor Recent Developments/Updates
6.2 Zetia
6.2.1 Zetia Corporation Information
6.2.2 Zetia Description and Business Overview
6.2.3 Zetia Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Zetia Cardiovascular Disease Nursing Drugs Product Portfolio
6.2.5 Zetia Recent Developments/Updates
6.3 Vytorin
6.3.1 Vytorin Corporation Information
6.3.2 Vytorin Description and Business Overview
6.3.3 Vytorin Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Vytorin Cardiovascular Disease Nursing Drugs Product Portfolio
6.3.5 Vytorin Recent Developments/Updates
6.4 Letairis
6.4.1 Letairis Corporation Information
6.4.2 Letairis Description and Business Overview
6.4.3 Letairis Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Letairis Cardiovascular Disease Nursing Drugs Product Portfolio
6.4.5 Letairis Recent Developments/Updates
6.5 Tracleer
6.5.1 Tracleer Corporation Information
6.5.2 Tracleer Description and Business Overview
6.5.3 Tracleer Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Tracleer Cardiovascular Disease Nursing Drugs Product Portfolio
6.5.5 Tracleer Recent Developments/Updates
6.6 Bystolic
6.6.1 Bystolic Corporation Information
6.6.2 Bystolic Description and Business Overview
6.6.3 Bystolic Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bystolic Cardiovascular Disease Nursing Drugs Product Portfolio
6.6.5 Bystolic Recent Developments/Updates
6.7 Opsumit
6.6.1 Opsumit Corporation Information
6.6.2 Opsumit Description and Business Overview
6.6.3 Opsumit Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Opsumit Cardiovascular Disease Nursing Drugs Product Portfolio
6.7.5 Opsumit Recent Developments/Updates
6.8 Ranexa
6.8.1 Ranexa Corporation Information
6.8.2 Ranexa Description and Business Overview
6.8.3 Ranexa Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Ranexa Cardiovascular Disease Nursing Drugs Product Portfolio
6.8.5 Ranexa Recent Developments/Updates
6.9 Azilva
6.9.1 Azilva Corporation Information
6.9.2 Azilva Description and Business Overview
6.9.3 Azilva Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Azilva Cardiovascular Disease Nursing Drugs Product Portfolio
6.9.5 Azilva Recent Developments/Updates
6.10 Remodulin
6.10.1 Remodulin Corporation Information
6.10.2 Remodulin Description and Business Overview
6.10.3 Remodulin Cardiovascular Disease Nursing Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Remodulin Cardiovascular Disease Nursing Drugs Product Portfolio
6.10.5 Remodulin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cardiovascular Disease Nursing Drugs Industry Chain Analysis
7.2 Cardiovascular Disease Nursing Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cardiovascular Disease Nursing Drugs Production Mode & Process
7.4 Cardiovascular Disease Nursing Drugs Sales and Marketing
7.4.1 Cardiovascular Disease Nursing Drugs Sales Channels
7.4.2 Cardiovascular Disease Nursing Drugs Distributors
7.5 Cardiovascular Disease Nursing Drugs Customers
8 Cardiovascular Disease Nursing Drugs Market Dynamics
8.1 Cardiovascular Disease Nursing Drugs Industry Trends
8.2 Cardiovascular Disease Nursing Drugs Market Drivers
8.3 Cardiovascular Disease Nursing Drugs Market Challenges
8.4 Cardiovascular Disease Nursing Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 循環器疾患看護薬のグローバル市場2023年：降圧薬、抗狭心症薬、抗凝固薬、抗高脂血症薬、抗心不全薬、抗不整脈薬(Global Cardiovascular Disease Nursing Drugs Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • ジピン系降圧剤のグローバル市場2023年：ニフェジピン、アムロジピンベシル酸塩、フェリジピン、ベニジピン、その他
  • 世界の代謝性疾患治療薬市場インサイト及び予測（グリコーゲン代謝病薬、脂質代謝病薬、アミノ酸代謝薬、その他）
  • 世界の慢性心不全(CHF)治療薬市場2022年：抗凝固薬（アスピリン）、抗血小板薬（クロピドグレル、プラスグレル、チカグレロル）、抗凝固薬（ワルファリン）、血圧維持薬（アンジオテンシン変換酵素（ACE）阻害剤）、アンジオテンシンII受容体遮断薬（ARB）、スタチン、利尿薬、硝酸塩
  • 世界の神経障害薬市場2022年：抗精神病薬、催眠薬、鎮静薬、鎮痛薬、抗凝固薬、その他
  • 世界の腎臓病治療薬市場2022年：錠剤、カプセル、その他